Lung Cancer Master Protocol (Lung-MAP), a public-private partnership, established infrastructure for conducting a biomarker-driven master protocol in molecularly targeted therapies. We compared ...
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of ...
A prototype service utilising satellites for mapping forests to aid compliance with the Kyoto Protocol has been endorsed by end users from European countries one environmental ministry representative ...
Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue. Researchers ...
MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine MOUNTAIN VIEW, Calif., Jan 16, 2008 -- MAP Pharmaceuticals, ...
Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study Lung Cancer Master Protocol (Lung-MAP), a public-private partnership, established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results